

Press Release

Recce Pharmaceuticals Delivers the Opening Address at World Antimicrobial Resistance Congress 2024

Sydney Australia, 6 September 2024: Recce Pharmaceuticals Limited (**ASX:RCE**, **FSE:R9Q**), (Recce or the **Company**), the Company developing a New Class of Synthetic Anti-Infectives, today delivers the **Opening Address** and the **Opening R&D Address**, as well as participate in a **Panel Discussion** focused on antimicrobial resistance (AMR), at the World AMR Congress 2024, being held September 5-6 in Philadelphia, Pennsylvania.

Details of the presentations below:



Title: *Never surrender: Mobilising the Global Fight Against Antibiotic Resistance*

Format: Opening Keynote Plenary

Date and Time: Thursday, September 5, 2024, at 9:00 a.m. EST

Participant: Alan W Dunton MD, Chief Medical Advisor and Non-Executive Director



Title: *The Promise of Recce Anti-Infectives: Tackling AMR with Cutting-edge Treatments*

Format: Opening R&D Address

Date and Time: Thursday, September 5, 2024, at 11:20 a.m. EST

Presenter: John Prendergast, Ph.D., Executive Chairman



Title: *AMR Awareness: The Next Important Step in our Battle*

Format: Panel

Date and Time: Thursday, September 5, 2024, at 2:15 p.m. EST

Participant: James Graham, Chief Executive Officer, and Managing Director

Since 2015, the two-day **World AMR Congress**, is the world's largest AMR conference with more than 1,500 attendees from over 50 countries and is the leading event globally for all stakeholders in the AMR space, advancing solutions to combat current and future pressing global health crises.



ASX: RCE, **FSE:** R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 **T** +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Click [here](#) to view the full agenda and **Recce's Participation at the World AMR Congress 2024.**

Kaylee Nguyen, Senior Conference Manager, World AMR Congress says: "Antimicrobial resistance is a critical global health crisis demanding immediate attention. Now more than ever, innovative drugs and new strategies are essential. The World AMR Congress remains a pivotal event, providing innovative companies like Recce with the opportunity to engage with global AMR stakeholders and drive initiatives to tackle this urgent challenge."



Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Media and Investor Relations

Australia
Andrew Geddes
CityPR
+61 408 677 734
ageddes@citypublicrelations.com.au

USA
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com